E3311 (NCT01898494) is a Phase II randomized study which showed favorable outcomes among intermediate risk HPV+ oropharynx cancer (OPC) patients who underwent transoral surgery (TOS) followed by pathology-guided or adapted, deintensified adjuvant treatment. Ranee Mehra, MD, University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, MD, explores survival outcomes based on tobacco history. No differences were observed in progression-free survival (PFS) or overall-survival (OS) outcomes at three years between patients with less than or greater than 10 pack year smoking history as well as current versus former smokers. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

свернуть